| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |